Comparative Pharmacology
Head-to-head clinical analysis: AMINOSYN 3 5 M IN PLASTIC CONTAINER versus AMINOSYN II 5 IN DEXTROSE 25 IN PLASTIC CONTAINER.
Head-to-head clinical analysis: AMINOSYN 3 5 M IN PLASTIC CONTAINER versus AMINOSYN II 5 IN DEXTROSE 25 IN PLASTIC CONTAINER.
AMINOSYN 3.5% M IN PLASTIC CONTAINER vs AMINOSYN II 5% IN DEXTROSE 25% IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Aminosyn 3.5% M is a mixture of essential and non-essential amino acids used for parenteral nutrition. It provides substrates for protein synthesis, thereby maintaining nitrogen balance and supporting tissue repair and growth.
Amino acids serve as substrates for protein synthesis and nitrogen balance; dextrose provides caloric energy. Dextrose stimulates insulin release, promoting cellular uptake of amino acids.
Intravenous infusion: 500 mL to 1 L of 3.5% amino acid solution per day for adults; rate not to exceed 0.1 g amino acids/kg/hr.
Intravenous administration based on protein requirements: 1.0-2.0 g/kg/day amino acids, corresponding to 20-40 mL/kg/day of AMINOSYN II 5% in DEXTROSE 25%. Typical adult dose starts at 30-40 mL/hour, titrated to metabolic goals.
None Documented
None Documented
Variable (minutes to hours) due to rapid metabolic utilization; terminal half-life in plasma is <10 minutes for most amino acids.
Not applicable as a single entity; amino acids have rapid plasma clearance (t1/2 of minutes to hours) and dextrose is rapidly cleared (t1/2 ~1-2 hours). Clinical context: Continuous infusion maintains steady state.
Renal: >90% as amino acids and metabolites; negligible biliary/fecal elimination.
Amino acids are primarily metabolized; nitrogen is excreted as urea (renal, ~85%) and ammonia (renal, ~2-5%); glucose is fully metabolized to CO2 and water (exhaled and renal); electrolytes are excreted renally. Less than 5% excreted unchanged renally.
Category C
Category C
Amino Acid Solution
Amino Acid Solution